2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障了产品有效 交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净化类和药械 组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态 势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产品研发和 市场开拓，本期药械组合类智能装备收入实现较大增长。 格隆汇2月26日丨迈得医疗(688310.SH)公布2025年度业绩快报，2025年公司实现营业收入4.47亿元，与 去年同期相比上升62.79%；实现营业利润5969.89万元，利润总额6122.32万元，实现归属于母公司所有 者的净利润6525.99万元，实现归属于母公司所有者的扣除非经常性损益的净利润5329.23万元，与去年 同期相比变动较大，实现扭亏为盈。 ...

Core Viewpoint - The company, Maide Medical (688310.SH), is expected to achieve significant revenue growth in 2025, with projected revenue of approximately 447 million yuan, representing an increase of about 173 million yuan or 62.81% year-on-year [1] Financial Performance - The company anticipates turning a profit in 2025, with a projected net profit attributable to shareholders of approximately 66.52 million yuan [1] - The expected net profit, excluding non-recurring gains and losses, is around 54.64 million yuan [1] Business Growth Drivers - The substantial revenue growth is attributed to the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasizes technological innovation and process iteration to enhance product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment sectors are performing well, particularly due to strong demand growth for medical consumables in the end market [1] - The optimistic market outlook for medical device combination intelligent equipment has led the company to focus on new product development and market expansion in this area [1]